Previous 10 | Next 10 |
2023-07-19 08:30:52 ET Aqua Metals ( AQMS ) -27% after disclosing stock offering . Amarin Corporation ( AMRN ) -20% on plan to undergo restructuring . Biophytis ( BPTS ) -18% on $3.8M offering . Genprex ( GNPX ) -14% on $7.5 Millio...
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathwa...
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathway...
2023-05-15 17:05:23 ET Aprea Therapeutics press release ( NASDAQ: APRE ): Q1 GAAP EPS of -$1.34. As of March 31, 2023, the Company reported cash and cash equivalents of $31.0 million. For further details see: Aprea Therapeutics GAAP EPS of -$1.34
DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage respons...
DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage respons...
2023-04-06 13:15:40 ET The following slide deck was published by Aprea Therapeutics, Inc. in conjunction with this event. For further details see: Aprea Therapeutics (APRE) Investor Presentation - Slideshow
Aprea Therapeutics, Inc. (NASDAQ: APRE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 9.43% on the day to $4.2. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes ca...
2023-04-06 10:02:19 ET Gainers: Bullfrog AI ( BFRG ) +16% . HUTCHMED (China) ( HCM ) +10% . Aprea Therapeutics ( APRE ) +8% . Clearside Biomedical ( CLSD ) +5% . Soleno Therapeutics ( SLNO ) +5% . Losers: Scilex ( SCLX ...
2023-03-31 00:49:09 ET Aprea Therapeutics press release ( NASDAQ: APRE ): Q4 GAAP EPS of -$0.92 beats by $2.30 . As of December 31, 2022, the Company reported cash and cash equivalents of $28.8 million compared to $53.1 million as of December 31, 2021. The Company beli...
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NASDAQ Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...